Caris Life Sciences (CAI) Change in Receivables (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Change in Receivables of -$21.6 million for Q1 2026, down 173.26% year-over-year from $29.5 million in Q1 2025, and down 123.76% quarter-over-quarter from $91.0 million in Q4 2025.
Caris Life Sciences (CAI) Change in Receivables (2024 - 2026) Analysis & Trends
Caris Life Sciences' Change in Receivables history runs 3 years deep, the most recent figure standing at -$21.6 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 173.26% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at $16.1 million (changed N/A YoY), while the FY2025 annual figure was $29.8 million, down 11.91% from the prior year.
- Change in Receivables for Q1 2026 stood at -$21.6 million, down from $91.0 million in the prior quarter.
- The five-year high for Change in Receivables was $91.0 million in Q4 2025, with the low at -$29.1 million in Q2 2025.
- The 3-year median for Change in Receivables is -$7.9 million (2025), against an average of $3.6 million.
- Peak annual rise in Change in Receivables reached 383.97% in 2025, while the deepest fall reached 1176.62% in 2025.
- Caris Life Sciences' Change in Receivables stood at $18.8 million in 2024, then soared by 383.97% to $91.0 million in 2025, then tumbled by 123.76% to -$21.6 million in 2026.
- Business Quant data shows CAI's Change in Receivables at -$21.6 million in Q1 2026, $91.0 million in Q4 2025, and -$24.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 26.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.37 Mn |
| Jun 30, 2026 | 26.37 Mn |
| Mar 31, 2026 | -21.62 Mn |
| Mar 31, 2026 | -21.62 Mn |
| Dec 31, 2025 | 91.02 Mn |
| Dec 31, 2025 | 91.02 Mn |
| Sep 30, 2025 | -24.19 Mn |
| Sep 30, 2025 | -24.19 Mn |
| Jun 30, 2025 | -29.13 Mn |
| Jun 30, 2025 | -29.13 Mn |
| Mar 31, 2025 | -7.91 Mn |
| Mar 31, 2025 | -7.91 Mn |
| Dec 31, 2024 | 18.81 Mn |
| Dec 31, 2024 | 18.81 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.90 Mn |